EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV

Jordan E Lake, Douglas W Kitch, Amy Kantor, Raja Muthupillai, Karin L Klingman iD, Christina Vernon, Pablo F Belaunzaran-Zamudio iD, Carl J Fichtenbaum iD, Sonya Heath, Hugo Perazzo iD, Kathleen Corey, Todd T Brown iD und 3 weitere

Annals of Internal Medicine · 2024-06 · 177 (6) · 835-838

DOI: 10.7326/m23-3354 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Annals of Internal Medicine, 2024-06. Verfasst von Jordan E Lake und 14 weiteren Autor:innen. Beteiligte Einrichtung: UTHealth Houston, Houston, Texas. Hauptthemen laut MEDLINE: HIV Infections, Glucagon-Like Peptides, Fatty Liver. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsGlucagon-Like PeptidesFatty LiverHumansMaleMiddle AgedFemaleAdultHypoglycemic AgentsSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • UTHealth Houston, Houston, Texas.
  • Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • School of Engineering Medicine, Texas A&M University, Houston, Texas, and ForeSpect PLLC, Pearland, Texas.
  • Weill Cornell College of Medicine, New York, New York.
  • Social & Scientific Systems, Inc., and FHI 360, Durham, North Carolina.
  • National Institute of Allergy and Infectious Diseases, Rockville, Maryland.

ORCID-Profile: Karin L Klingman, Pablo F Belaunzaran-Zamudio, Carl J Fichtenbaum, Hugo Perazzo, Todd T Brown, Kristine M Erlandson

Förderung

  • NIAID NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Klingman, K. L., Vernon, C., Belaunzaran-Zamudio, P. F., Fichtenbaum, C. J., Heath, S., Perazzo, H., Corey, K., Brown, T. T., Landay, A., Sattler, F., & Erlandson, K. M. (2024). The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV. Annals of Internal Medicine, 177(6), 835-838. https://doi.org/10.7326/m23-3354

Vancouver

Lake JE, Kitch DW, Kantor A, Muthupillai R, Klingman KL, Vernon C, et al. The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV. Annals of Internal Medicine. 2024;177(6):835-838. doi:10.7326/m23-3354

BibTeX
@article{Lake2024,
  author = {Lake, Jordan E and Kitch, Douglas W and Kantor, Amy and Muthupillai, Raja and Klingman, Karin L and Vernon, Christina and Belaunzaran-Zamudio, Pablo F and Fichtenbaum, Carl J and Heath, Sonya and Perazzo, Hugo and Corey, Kathleen and Brown, Todd T and Landay, Alan and Sattler, Fred and Erlandson, Kristine M},
  title = {The Effect of Open-Label Semaglutide on Metabolic Dysfunction–Associated Steatotic Liver Disease in People With HIV},
  journal = {Annals of Internal Medicine},
  year = {2024},
  volume = {177},
  number = {6},
  pages = {835--838},
  doi = {10.7326/m23-3354}
}
Kostenlos starten →